SCHEMBL3520489

SCHEMBL3520489

COc1ccccc1-c1cnc2c(C(=O)NCC(=O)O)c(O)ccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.52
ATR Q13535 1/20 0.45
EGLN1 Q9GZT9 3/20 0.43
TACR3 P29371 1/20 0.42
FTO Q9C0B1 4/20 0.42
KDM5B Q9UGL1 3/20 0.42
KDM2A Q9Y2K7 3/20 0.42
KDM6B O15054 2/20 0.42
KDM4C Q9H3R0 1/20 0.42
KDM3A Q9Y4C1 1/20 0.42
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ABL1 P00519 1/20 0.41
KDM1A O60341 1/20 0.40
HDAC1 Q13547 1/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518484 0.91 EGLN3 (0.47) EGLN3ATREGLN1FTOKDM5B
SCHEMBL3518299 0.89 EGLN3 (0.49) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3518292 0.89 EGLN3 (0.49) EGLN3ATREGLN1FTOKDM5B
SCHEMBL3520841 0.87 EGLN3 (0.47) EGLN3EGLN1MEN1KMT2ASMN1; SMN2
SCHEMBL3757200 0.87 EGLN3 (0.57) EGLN3ATREGLN1FTOKDM5B
SCHEMBL3519422 0.85 EGLN3 (0.53) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3518710 0.85 EGLN3 (0.54) EGLN3ATREGLN1TACR3FTO
SCHEMBL3522327 0.84 EGLN3 (0.52) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3521806 0.84 EGLN3 (0.52) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3520878 0.83 EGLN3 (0.51) EGLN3EGLN1MEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US claimed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP claimed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO claimed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885ATR 4548/4885EGLN1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.